J&J: adjusted EPS up 19.3% in Q3
(CercleFinance.com) - J&J has announced that its Q3 sales reached $21.
3bn, up 6.8% y-o-y.
Adjusted net profit was $6.77bn, up 14.1%, giving adjusted EPS of $2.66 (+19.3%).
Management said that by focusing on innovative solutions in medicine and medical technology, Johnson & Johnson is innovating across the spectrum of healthcare and is poised to deliver the medical breakthroughs of tomorrow.
The company believes that the strong results and significant pipeline advances in Q3 provide a solid foundation for sustained future growth.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
3bn, up 6.8% y-o-y.
Adjusted net profit was $6.77bn, up 14.1%, giving adjusted EPS of $2.66 (+19.3%).
Management said that by focusing on innovative solutions in medicine and medical technology, Johnson & Johnson is innovating across the spectrum of healthcare and is poised to deliver the medical breakthroughs of tomorrow.
The company believes that the strong results and significant pipeline advances in Q3 provide a solid foundation for sustained future growth.
Copyright (c) 2023 CercleFinance.com. All rights reserved.